Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
Enregistré dans:
Auteur principal: | Juan Tamargo |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Radcliffe Medical Media
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f7f531e9dbad468e8cec0e108f45481d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
par: Juan Tamargo
Publié: (2019) -
Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
par: Muhammad Shahzeb Khan, et autres
Publié: (2019) -
Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
par: Thomas A Zelniker, et autres
Publié: (2019) -
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
par: Giuseppe Rosano, et autres
Publié: (2020) -
Corrigendum to: Pulmonary Hypertension in Heart Failure Patients
par: Sriram D Rao, et autres
Publié: (2020)